Scarica l'app Stockscreener
8.81
5.17%
-0.48
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
CEO Moves: Why is Vanda Pharmaceuticals Inc stock going up2026 Market Overview & Precise Swing Trade Alerts - baoquankhu1.vn
Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN
DC Circ. Spends Hours Debating 'Same' Generic Label Reqs - Law360
Vanda Pharmaceuticals Hits New 52-Week High of $9.94, Surges 59.87% - Markets Mojo
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com Nigeria
Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid - simplywall.st
Vanda Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Growth Insights - Investing.com Canada
VNDA: BYSANTI and Nereus launches drive growth, with key pipeline milestones expected by year-end - TradingView
Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy - TipRanks
Vanda Pharmaceuticals (NASDAQ: VNDA) CEO outlines DTC channel for FDA-approved motion drug - Stock Titan
Vanda Pharmaceuticals (NASDAQ:VNDA) Sets New 52-Week HighWhat's Next? - MarketBeat
What's going on with Vanda Pharma stock Tuesday? - MSN
Vanda Pharmaceuticals (NASDAQ:VNDA) Trading Up 8.1%Should You Buy? - MarketBeat
Vanda surges as FDA approves Bysanti for bipolar disorder, schizophrenia - MSN
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Truist Financial Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline By Investing.com - Investing.com Australia
Truist Securities Initiates Coverage on Vanda Pharmaceuticals (V - GuruFocus
Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target - marketscreener.com
Vanda Pharmaceuticals (NASDAQ:VNDA) CMO Joakim Wijkstrom Sells 30,800 Shares - MarketBeat
Kevin Patrick Moran Sells 42,442 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat
Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) SVP Sells 42,434 Shares of Stock - MarketBeat
Gunther Birznieks Sells 42,431 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat
Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) CEO Sells 156,235 Shares of Stock - MarketBeat
Executive at Vanda (NASDAQ: VNDA) sells shares to cover RSU taxes - Stock Titan
[Form 4] Vanda Pharmaceuticals Inc. Insider Trading Activity - Stock Titan
Vanda (NASDAQ: VNDA) CEO sells 156,235 shares to cover RSU tax obligations - Stock Titan
Vanda Pharmaceuticals (VNDA) SVP sells 42,431 shares to cover RSU tax - Stock Titan
VNDA SEC FilingsVanda Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Q1 Earnings Estimate for VNDA Issued By HC Wainwright - MarketBeat
VNDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
After years of dispute with FDA, Vanda will get a public hearing for jet lag drug - Endpoints News
FDA Grants Rare Hearing for Vanda Pharmaceuticals' (VNDA) Jet La - GuruFocus
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
Vanda secures win in regulatory showdown as FDA agrees to review jet lag drug - The Business Journals
Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years - marketscreener.com
Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag - marketscreener.com
Vanda Pharmaceuticals (VNDA) Secures Rare FDA Hearing for Hetlio - GuruFocus
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - Finviz
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - Morningstar
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
[144] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
Document - SEC.gov
EMA Turns Down Vanda’s Iloperidone And Acadia’s Daybu, Backs 12 Others For EU Approval - Citeline News & Insights
Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone - marketscreener.com
Vanda Pharmaceuticals Announces Participation in the 2026 Citize - GuruFocus
Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference - Intellectia AI
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference - ChartMill
A Look At Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of Bysanti For Bipolar I Disorder And Schizophrenia - simplywall.st
Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley - Yahoo Finance
Vanda Pharmaceuticals Inc. (VNDA) Stock Analysis: A Biotech Contender with Nearly 80% Upside Potential - DirectorsTalk Interviews
Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug - Benzinga
Vanda skin disorder drug accepted for FDA review - MSN
Vanda Pharmaceuticals Says US FDA Accepts Imsidolimab BLA for Rare Skin Disease - marketscreener.com
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Asianet Newsable
B. Riley Adjusts Vanda Pharmaceuticals Price Target to $17 From $14, Maintains Buy Rating - marketscreener.com
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - The Malaysian Reserve
Vanda Pharmaceuticals Seeks FDA Approval for Imsidolimab - Intellectia AI
Vanda Pharmaceuticals (VNDA) Gains on FDA Review Acceptance for Imsidolimab - GuruFocus
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):